Biotricity, Inc. (BTCY) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong revenue growth, improved profitability, and positive EBITDA, indicating a solid financial performance. Product development and market expansion efforts are promising, with a focus on AI and international distribution. Despite some risks, such as regulatory approvals and sales strategy, the overall sentiment is positive due to strategic initiatives and operational efficiencies. With no negative sentiment from the Q&A, the stock price is likely to increase by 2% to 8% over the next two weeks.
Key Financial Performance
Revenue Revenue increased by 10.2% year-over-year to $4 million from $3.6 million in the prior year quarter. This growth is attributed to the efficacy of strategic initiatives and technological advancements.
Gross Profit Gross profit totaled $3.3 million, up 17.6% from $2.8 million in the prior year period. The gross profit percentage improved by 516 basis points to 81.5% from 76.4% in the prior year quarter. This increase is due to the expansion of recurring technology fee revenue and efficiencies gained through proprietary AI and improvements in monitoring and cloud cost structures.
Operating Expenses Operating expenses were $2.8 million, a 4.2% decrease from $2.93 million in the prior year period. Selling, general, and administrative expenses decreased by 8.2%, while R&D expenses increased by $72,000. The decrease in operating expenses is attributed to strategic transformations in the sales force and proactive cost management.
EBITDA EBITDA was $280,000, marking the third consecutive quarter of positive EBITDA. This corresponds to $0.01 per share. The improvement in operating results by nearly $1 million contributed to this milestone.
Net Loss Net loss attributable to common stockholders was $1.1 million compared to $1.3 million in the prior year period. Loss per share improved to $0.042 from $0.054 in the prior year period. The reduction in net loss is due to revenue growth, operating efficiencies, and cost management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Cardiac AI Cloud Platform: Expanded to enhance diagnostic accuracy, improve patient outcomes, and increase clinical profitability. Pursuing FDA clearance for groundbreaking AI clinical model.
Bioheart: Extended care beyond clinics by providing clinical quality tools directly to consumers, enabling early identification of meaningful changes and lifestyle adjustments.
Biocore Pro: Next-generation cardiac monitoring device with cellular connectivity. Expanded sales and launched large-scale pilot programs in hospital networks and clinic groups.
Geographic Expansion: Pursuing international regulatory approvals in addition to existing approvals in the U.S., Canada, Saudi Arabia, Argentina, and other smaller markets. Focus remains on U.S. market expansion with opportunistic international distribution partnerships.
GPO Networks: Contracted under 3 of the largest GPO networks, providing access to over 90% of U.S. hospitals.
Revenue Growth: Revenue increased by 10.2% to $4 million compared to the prior year quarter. Gross profit improved by 17.6% to $3.3 million, with gross profit percentage rising to 81.5%.
Operational Efficiencies: Achieved positive EBITDA for the third consecutive quarter ($280,000). Operating expenses decreased by 4.2%, with selling, general, and admin expenses reduced by 8.2%.
Technology-as-a-Service Model: Primary subscription model driving recurring revenue growth. Secondary usage-based subscription model also robust.
Sales Strategy: Focused on longer sales cycles for larger accounts, including independent hospitals and GPO networks. Expanded into ancillary verticals aligned with core business.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The company is pursuing FDA clearance for its AI clinical model and additional international regulatory approvals. Delays or failures in obtaining these approvals could hinder product distribution and growth.
Market Expansion: While focusing on U.S. market expansion, the company is also expanding internationally through distribution partnerships. Challenges in penetrating new markets or managing distribution partnerships could impact growth.
Operational Costs: Although operating expenses have decreased, the company is still incurring net losses. Sustained cost management and achieving profitability remain critical challenges.
Sales Strategy: The company has transformed its sales force to focus on longer sales cycles and larger accounts, which may delay revenue realization and pose risks if these strategies do not yield expected results.
Technology Development: The company is heavily reliant on its AI-driven platform and next-generation devices. Any setbacks in technology development or FDA clearance could impact its competitive edge and revenue growth.
Economic and Market Conditions: The company’s growth is tied to demand for remote patient management solutions, which could be affected by economic uncertainties or changes in healthcare funding.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company anticipates further revenue growth in the coming quarters, driven by the adoption of its flagship device, Biocore Pro, which is designed for use in hospitals and large clinics.
Profitability: Biotricity expects to achieve profitability in the next quarter, building on its third consecutive quarter of positive EBITDA and free cash flows.
Market Expansion: The company is pursuing regulatory approvals internationally to prepare for future distribution, while maintaining a primary focus on U.S. market expansion. It is also expanding its geographic footprint and exploring ancillary verticals that align with its core business.
Product Development: Biotricity is advancing its AI-driven cardiac monitoring platform and pursuing FDA clearance for its AI clinical model, which is expected to improve operational expenses and margins upon approval.
Customer Adoption: The company expects continued strong adoption of Biocore Pro across existing and new customers, supported by current demand and pipeline visibility.
Operational Efficiency: Biotricity plans to continue leveraging AI and automation to improve operating efficiencies and cost management, contributing to sustained growth and profitability.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are there any questions from the participants?
A:There are no questions at this time.
Q:What are the company's prospects for 2026 and financial expectations for this year?
A:The company is very excited about the prospects of 2026. They believe the top line of the company will continue to grow, and they expect to turn net income positive this year.
Q:Review of Unclear Management Responses
A:No questions were avoided or lacked clarity as there were no participant questions, and the management provided a clear response regarding their financial expectations and future prospects.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Arabia Argentina
Argentina market
Biotricity Financial
Biotricity Founder
Biotricity figure
Biotricity others
Biotricity press
Biotricity quarter
Biotricity statement
Biotricity transition
Biotricity website
Canada Saudi
Chairman today
Demand patient
Dr Waqaas
Siddiq sir
Waqaas Al
access workflow
account achievement
accuracy reimbursement
addition approval
adjustment term
adoption expansion
afternoon Biotricity
alignment infrastructure
approach partner
approval Canada
approval addition
approval distribution
breakeven demand
care technology
clearance
platform
press release
provider
resource
result
BTCY Transcript
Biotricity, Inc. (BTCY) Q3 2026 Earnings Call Transcript
Positive2-11
The earnings call highlights strong revenue growth, improved profitability, and positive EBITDA, indicating a solid financial performance. Product development and market expansion efforts are promising, with a focus on AI and international distribution. Despite some risks, such as regulatory approvals and sales strategy, the overall sentiment is positive due to strategic initiatives and operational efficiencies. With no negative sentiment from the Q&A, the stock price is likely to increase by 2% to 8% over the next two weeks.
Biotricity, Inc. (BTCY) Q2 2026 Earnings Call Transcript
Positive11-14
The earnings call highlights strong revenue growth, improved profitability, and strategic market expansion. While there are risks, such as regulatory hurdles and market penetration challenges, the company's positive free cash flows, improved gross profit margins, and strategic partnerships contribute to a favorable outlook. The absence of negative sentiment in the Q&A session further supports a positive sentiment. Despite a net loss, the reduction in losses and positive EBITDA indicate progress towards profitability, leading to a predicted stock price movement in the 2% to 8% range over the next two weeks.
Biotricity, Inc. (BTCY) Q4 2025 Earnings Conference Call Transcript
Positive7-18
The earnings call highlights strong financial performance with a 16.5% YoY revenue increase and a significant improvement in gross margins. Operating expenses have decreased, and there is progress towards profitability with positive adjusted EBITDA in Q4. The Q&A section reveals some uncertainties, but overall, management's optimism and strategic initiatives, like international expansion and data monetization, are positive. Despite some vague timelines, the company's strong financials and strategic plans outweigh the risks, suggesting a positive stock price movement.
Biotricity, Inc. (BTCY) Q2 2025 Earnings Call Transcript
Neutral11-16
BTCY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
